Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Large healthcare related equities associated with Obamacare. Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Viatris (MYL)
The company has Return on Asset of 3.63 % which means that on every $100 spent on assets, it made $3.63 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 2.22 %, implying that it generated $2.22 on every 100 dollars invested. Viatris' management efficiency ratios could be used to measure how well Viatris manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Mid-Cap' category with a total capitalization of 8.59 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Viatris's market, we take the total number of its shares issued and multiply it by Viatris's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Select Medical Holdings (SEM)
The company has Return on Asset of 0.0452 % which means that on every $100 spent on assets, it made $0.0452 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2022 %, implying that it generated $0.2022 on every 100 dollars invested. Select Medical's management efficiency ratios could be used to measure how well Select Medical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Select Medical's Return On Capital Employed is very stable compared to the past year. As of the 24th of April 2024, Return On Equity is likely to grow to 0.20, while Return On Tangible Assets are likely to drop 0.06. At this time, Select Medical's Asset Turnover is very stable compared to the past year. The firm currently falls under 'Mid-Cap' category with a total capitalization of 3.62 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Select Medical's market, we take the total number of its shares issued and multiply it by Select Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.0269 % which means that on every $100 spent on assets, it made $0.0269 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0387 %, implying that it generated $0.0387 on every 100 dollars invested. Cooper Companies' management efficiency ratios could be used to measure how well Cooper Companies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.06. Also, Return On Capital Employed is likely to grow to 0.05. At this time, Cooper Companies' Other Assets are very stable compared to the past year. As of the 24th of April 2024, Net Tangible Assets is likely to grow to about 2.7 B, while Intangibles To Total Assets are likely to drop 0.32. The firm currently falls under 'Large-Cap' category with a total capitalization of 18.22 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cooper Companies's market, we take the total number of its shares issued and multiply it by Cooper Companies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Cooper Companies shows a prevailing Real Value of $78.02 per share. The current price of the firm is $90.2. Our model approximates the value of Cooper Companies from analyzing the firm fundamentals such as Operating Margin of 0.16 %, profit margin of 0.08 %, and Return On Equity of 0.0387 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Stryker (SYK)
The company has Return on Asset of 0.0687 % which means that on every $100 spent on assets, it made $0.0687 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1798 %, implying that it generated $0.1798 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stryker's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.10. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B. This firm currently falls under 'Mega-Cap' category with a total capitalization of 127.42 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Stryker's market, we take the total number of its shares issued and multiply it by Stryker's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of (0.1003) % which means that it has lost $0.1003 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2989) %, meaning that it created substantial loss on money invested by shareholders. Nevro Corp's management efficiency ratios could be used to measure how well Nevro Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.17. In addition to that, Return On Capital Employed is likely to drop to -0.19. At this time, Nevro Corp's Non Current Assets Total are very stable compared to the past year. As of the 24th of April 2024, Intangible Assets is likely to grow to about 33 M, while Total Assets are likely to drop about 461.8 M. This firm currently falls under 'Small-Cap' category with a current market capitalization of 469.16 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nevro Corp's market, we take the total number of its shares issued and multiply it by Nevro Corp's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Nevro Corp secures a last-minute Real Value of $11.61 per share. The latest price of the firm is $12.51. Our model forecasts the value of Nevro Corp from analyzing the firm fundamentals such as Profit Margin of (0.22) %, return on equity of -0.3, and Current Valuation of 364.63 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend obtaining undervalued stocks and abandoning overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Abbott Laboratories (ABT)
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 186.69 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abbott Laboratories's market, we take the total number of its shares issued and multiply it by Abbott Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Return On Tangible Assets is likely to gain to -0.03 in 2024. Return On Capital Employed is likely to gain to -0.02 in 2024. At this time, Catalent's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 157.5 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 6.2 B in 2024. Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a current market capitalization of 10.14 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Catalent's market, we take the total number of its shares issued and multiply it by Catalent's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Catalent shows a prevailing Real Value of $61.47 per share. The current price of the firm is $55.95. Our model approximates the value of Catalent from analyzing the firm fundamentals such as Profit Margin of (0.32) %, return on equity of -0.3, and Current Valuation of 14.91 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Zoetis Inc (ZTS)
The company has Return on Asset of 0.1315 % which means that on every $100 spent on assets, it made $0.1315 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4982 %, implying that it generated $0.4982 on every 100 dollars invested. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to gain to 0.17 in 2024, whereas Return On Tangible Assets are likely to drop 0.12 in 2024. At this time, Zoetis' Intangible Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 336.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.6 B in 2024. The entity currently falls under 'Large-Cap' category with a total capitalization of 68.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Zoetis's market, we take the total number of its shares issued and multiply it by Zoetis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Macroaxis Gross Profit
Macroaxis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Macroaxis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Macroaxis Gross Profit growth over the last 10 years. Please check Macroaxis' gross profit and other fundamental indicators for more details.
Story appears to be empty
Viatris (MYL)
The company has Return on Asset of 3.63 % which means that on every $100 spent on assets, it made $3.63 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 2.22 %, implying that it generated $2.22 on every 100 dollars invested. Viatris' management efficiency ratios could be used to measure how well Viatris manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Mid-Cap' category with a total capitalization of 8.59 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Viatris's market, we take the total number of its shares issued and multiply it by Viatris's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Select Medical Holdings (SEM)
The company has Return on Asset of 0.0452 % which means that on every $100 spent on assets, it made $0.0452 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2022 %, implying that it generated $0.2022 on every 100 dollars invested. Select Medical's management efficiency ratios could be used to measure how well Select Medical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Select Medical's Return On Capital Employed is very stable compared to the past year. As of the 24th of April 2024, Return On Equity is likely to grow to 0.20, while Return On Tangible Assets are likely to drop 0.06. At this time, Select Medical's Asset Turnover is very stable compared to the past year. The firm currently falls under 'Mid-Cap' category with a total capitalization of 3.62 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Select Medical's market, we take the total number of its shares issued and multiply it by Select Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.0269 % which means that on every $100 spent on assets, it made $0.0269 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0387 %, implying that it generated $0.0387 on every 100 dollars invested. Cooper Companies' management efficiency ratios could be used to measure how well Cooper Companies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.06. Also, Return On Capital Employed is likely to grow to 0.05. At this time, Cooper Companies' Other Assets are very stable compared to the past year. As of the 24th of April 2024, Net Tangible Assets is likely to grow to about 2.7 B, while Intangibles To Total Assets are likely to drop 0.32. The firm currently falls under 'Large-Cap' category with a total capitalization of 18.22 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cooper Companies's market, we take the total number of its shares issued and multiply it by Cooper Companies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Cooper Companies shows a prevailing Real Value of $78.02 per share. The current price of the firm is $90.2. Our model approximates the value of Cooper Companies from analyzing the firm fundamentals such as Operating Margin of 0.16 %, profit margin of 0.08 %, and Return On Equity of 0.0387 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor obtaining undervalued instruments and abandoning overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Stryker (SYK)
The company has Return on Asset of 0.0687 % which means that on every $100 spent on assets, it made $0.0687 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1798 %, implying that it generated $0.1798 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stryker's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.10. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B. This firm currently falls under 'Mega-Cap' category with a total capitalization of 127.42 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Stryker's market, we take the total number of its shares issued and multiply it by Stryker's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of (0.1003) % which means that it has lost $0.1003 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2989) %, meaning that it created substantial loss on money invested by shareholders. Nevro Corp's management efficiency ratios could be used to measure how well Nevro Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.17. In addition to that, Return On Capital Employed is likely to drop to -0.19. At this time, Nevro Corp's Non Current Assets Total are very stable compared to the past year. As of the 24th of April 2024, Intangible Assets is likely to grow to about 33 M, while Total Assets are likely to drop about 461.8 M. This firm currently falls under 'Small-Cap' category with a current market capitalization of 469.16 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nevro Corp's market, we take the total number of its shares issued and multiply it by Nevro Corp's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Nevro Corp secures a last-minute Real Value of $11.61 per share. The latest price of the firm is $12.51. Our model forecasts the value of Nevro Corp from analyzing the firm fundamentals such as Profit Margin of (0.22) %, return on equity of -0.3, and Current Valuation of 364.63 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend obtaining undervalued stocks and abandoning overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Abbott Laboratories (ABT)
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 186.69 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abbott Laboratories's market, we take the total number of its shares issued and multiply it by Abbott Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Return On Tangible Assets is likely to gain to -0.03 in 2024. Return On Capital Employed is likely to gain to -0.02 in 2024. At this time, Catalent's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 157.5 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 6.2 B in 2024. Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a current market capitalization of 10.14 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Catalent's market, we take the total number of its shares issued and multiply it by Catalent's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Catalent shows a prevailing Real Value of $61.47 per share. The current price of the firm is $55.95. Our model approximates the value of Catalent from analyzing the firm fundamentals such as Profit Margin of (0.32) %, return on equity of -0.3, and Current Valuation of 14.91 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Zoetis Inc (ZTS)
The company has Return on Asset of 0.1315 % which means that on every $100 spent on assets, it made $0.1315 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4982 %, implying that it generated $0.4982 on every 100 dollars invested. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to gain to 0.17 in 2024, whereas Return On Tangible Assets are likely to drop 0.12 in 2024. At this time, Zoetis' Intangible Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 336.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.6 B in 2024. The entity currently falls under 'Large-Cap' category with a total capitalization of 68.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Zoetis's market, we take the total number of its shares issued and multiply it by Zoetis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Portfolio Dashboard Now
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
